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Background
Since its implementation more than a decade ago combi-
nation Antiretroviral Therapy (ART) has had a dramatic
effect on HIV-1 induced mortality and morbidity. How-
ever, 15-20% of the patients initiating ART do not regain
CD4 T-cells despite an effective suppression of HIV1-
mRNA levels in blood. The incomplete therapeutic effect
leaves these patients at elevated risk of disease complica-
tions and death. Attempts to reduce clinical events
through IL-2 induced stimulation of CD4 T-cells in the
ESPRIT and SILCAAT studies have not proven to be suc-
cessful. Until further research has given better opportuni-
ties for a successful direct induction of functional CD4
cells a logical alternative may be to increase CD4 counts
indirectly by improving anti-HIV effect while on ART
using antigen-specific immune stimulation with an effec-
tive HIV-vaccine.
Methods
In a Phase II trial with Vacc-4x, a synthetic and specific
peptide vaccine to HIV-1 p24Gag, the increase of CD4
cells was studied in 37 chronically infected HIV patients
on ART and with varying baseline CD4 T-cell counts. The
median duration of ART prior to Vacc-4x immunization
was 4.5 years and preART CD4 counts were median 295
cells/uL.
Results
The average increase of CD4 counts was 9% (P < 0,05)
above baseline at 585 cell/uL (mean) 6 weeks after immu-
nization. For patients with baseline CD4 level <500 cells/
uL (n = 11) the increase was 25% (P < 0,05) or 105 cells/
uL. Only a few patients had a baseline CD4 count <400 (n
= 3) with an average increase of 32% (NS).
Conclusion
Patients on ART immunized with Vacc-4x experienced
increased CD4 counts. The effect appeared more pro-
nounced in patients with lower baseline CD4 counts
(<400-500). In a previous study (ACTG 384) CD4
increase for patients (preART CD4<300) was minimal
after 120 weeks on ART (RobbinsCID 2009,48, 350-61).
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